Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CB307,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Sofinnova Partners
Deal Size : $32.0 million
Deal Type : Financing
Details : The proceeds will fund development of Crescendo's ongoing Phase 1b clinical trial of CB307 (tri-specific humabody) through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort in individuals with PSMA+ metastatic castration-resist...
Product Name : CB307
Product Type : Antibody
Upfront Cash : Undisclosed
July 24, 2023
Lead Product(s) : CB307,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Sofinnova Partners
Deal Size : $32.0 million
Deal Type : Financing
Details : CB307 is a CD137/PSMA dual inhibitor protein drug candidate administered via intravenous infusion for PSMA positive metastatic castration-resistant prostate cancer.
Product Name : CB307
Product Type : Antibody
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : BioNTech
Deal Size : $790.0 million
Deal Type : Collaboration
Details : Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against cancer a...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $40.0 million
October 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : BioNTech
Deal Size : $790.0 million
Deal Type : Collaboration
Crescendo Biologics Expands its Ongoing Collaboration with Takeda
Details : The expansion will enable Takeda to access a range of Crescendo’s half-life extension Humabodies for use with its two Humabody programmes, licensed in November 2018 and July 2019.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 12, 2020
Reset All
